Barinthus Biotherapeutics (BRNS) Non-Current Deferred Tax Liability (2023 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Non-Current Deferred Tax Liability came in at $237000.0 in Q1 2026, down 43.03% YoY from $416000.0 in Q1 2025, and down 6.69% on a QoQ basis from $254000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $237000.0 in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 43.03% year-over-year to $237000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237000.0 (down 43.03% YoY) and the FY2025 annual result came in at $254000.0, down 97.52% from the prior year.
- Non-Current Deferred Tax Liability declined to $237000.0 in Q1 2026, from $254000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $11.8 million in Q4 2023 to a low of $237000.0 in Q1 2026.
- A 4-year average of $3.0 million and a median of $403500.0 in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability retreated 12.76% — and 2025, when it tumbled 97.52%.
- Tracing BRNS's Non-Current Deferred Tax Liability over 4 years: stood at $11.8 million in 2023, then slipped by 12.76% to $10.3 million in 2024, then plunged by 97.52% to $254000.0 in 2025, then retreated by 6.69% to $237000.0 in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $237000.0 (Q1 2026), $254000.0 (Q4 2025), and $320000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215,000.00 |
| Jun 30, 2026 | 215,000.00 |
| Mar 31, 2026 | 237,000.00 |
| Mar 31, 2026 | 237,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Sep 30, 2025 | 320,000.00 |
| Sep 30, 2025 | 320,000.00 |
| Jun 30, 2025 | 391,000.00 |
| Jun 30, 2025 | 391,000.00 |
| Mar 31, 2025 | 416,000.00 |
| Mar 31, 2025 | 416,000.00 |
| Dec 31, 2024 | 10.25 Mn |
| Dec 31, 2024 | 10.25 Mn |
| Sep 30, 2024 | 457,000.00 |
| Sep 30, 2024 | 457,000.00 |
| Dec 31, 2023 | 11.75 Mn |
| Dec 31, 2023 | 11.75 Mn |